NASDAQ:VERUVeru Stock Price, Forecast & News

$3.64

-0.05 (-1.36 %)

(As of 05/22/2020 04:00 PM ET)

Add

Compare

Today's Range

$3.52

Now: $3.64▼

$3.70

50-Day Range

$3.01

MA: $3.41▼

$4.02

52-Week Range

$1.67

Now: $3.64▼

$4.74

Volume423,250 shs

Average Volume516,747 shs

Market Capitalization$240.60 million

P/E RatioN/A

Dividend YieldN/A

Beta0.44

Veru Inc. operates as an oncology and urology biopharmaceutical company. The company operates through two segments, Commercial, and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation. The company's urology drug candidates include Tamsulosin delayed release sachet and Tamsulosin XR capsules that are under bioequivalence study for the treatment of benign prostatic hyperplasia; and Solifenacin delayed release granules, which is under bioequivalence study for the treatment of overactive bladder. Its urology drug candidates also comprise Tadalafil and Finasteride combination capsules that are under bioequivalence study for the treatment of men with lower urinary tract symptoms and enlarged prostate. The company's oncology drug candidate includes VERU-944, which is in Phase II clinical trial for the treatment of hot flashes in men on prostate cancer hormonal therapies; and VERU-111, an oral alpha and beta tubulin inhibitor, which is under Phase 1b/2 study for the treatment of metastatic prostate, breast, endometrial, ovarian, and pancreatic cancers. It serves agencies, health care distributors, non-government organizations, ministries of health, and other governmental agencies through distributors and retailers primarily in the United States, Brazil, Spain, France, and the United Kingdom. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was founded in 1896 and is headquartered in Miami, Florida.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Veru has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $8.25, Veru has a potential upside of 126.6% from its current price of $3.64.
Amount of Analyst Coverage
Veru has only been the subject of 2 research reports in the past 90 days.

2.9 Community Rank

Outperform Votes
Veru has received 230 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Veru has received 169 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Veru has received 57.64% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Veru and other stocks. Vote “Outperform” if you believe VERU will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VERU will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Veru does not currently pay a dividend.
Dividend Growth
Veru does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Veru insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 26.10% of the stock of Veru is held by insiders.
Percentage Held by Institutions
Only 13.16% of the stock of Veru is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Veru are expected to grow in the coming year, from ($0.14) to ($0.12) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Veru is -24.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Veru is -24.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Veru has a P/B Ratio of 7.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.41 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Fabricated rubber products, not elsewhere classified

Sub-IndustryPersonal Products

SectorMedical

Current SymbolNASDAQ:VERU

Previous Symbol

CUSIP31446210

CIK863894

Webwww.veruhealthcare.com

Phone305-509-6897

Debt

Debt-to-Equity Ratio0.07

Current Ratio1.04

Quick Ratio0.68

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$31.80 million

Price / Sales7.57

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.47 per share

Price / Book7.74

Profitability

EPS (Most Recent Fiscal Year)($0.19)

Net Income$-12,020,000.00

Net Margins-25.53%

Return on Equity-31.14%

Return on Assets-18.27%

Miscellaneous

Employees171

Outstanding Shares66,100,000

Market Cap$240.60 million

Next Earnings Date8/13/2020 (Estimated)

OptionableOptionable

Receive VERU News and Ratings via Email

Sign-up to receive the latest news and ratings for VERU and its competitors with MarketBeat's FREE daily newsletter.

Veru (NASDAQ:VERU) Frequently Asked Questions

How has Veru's stock been impacted by COVID-19 (Coronavirus)?

Veru's stock was trading at $3.20 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, VERU stock has increased by 13.8% and is now trading at $3.64. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Veru?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veru in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Veru.

When is Veru's next earnings date?

Veru is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Veru.

How were Veru's earnings last quarter?

Veru Inc (NASDAQ:VERU) announced its quarterly earnings data on Wednesday, May, 13th. The company reported ($0.01) EPS for the quarter, topping analysts' consensus estimates of ($0.04) by $0.03. The company had revenue of $9.94 million for the quarter, compared to analysts' expectations of $11.06 million. Veru had a negative net margin of 25.53% and a negative return on equity of 31.14%. View Veru's earnings history.

What price target have analysts set for VERU?

4 equities research analysts have issued twelve-month target prices for Veru's shares. Their forecasts range from $6.00 to $12.00. On average, they anticipate Veru's stock price to reach $8.25 in the next twelve months. This suggests a possible upside of 126.6% from the stock's current price. View analysts' price targets for Veru.

Has Veru been receiving favorable news coverage?

News stories about VERU stock have been trending extremely negative recently, InfoTrie reports. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Veru earned a news sentiment score of -4.5 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near future. View the latest news aboutVeru.

Are investors shorting Veru?

Veru saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 177,000 shares, a decrease of 48.7% from the April 30th total of 344,900 shares. Based on an average trading volume of 309,200 shares, the days-to-cover ratio is currently 0.6 days. Approximately 0.4% of the company's shares are sold short. View Veru's Current Options Chain.

Who are some of Veru's key competitors?

Some companies that are related to Veru include Estee Lauder Companies (EL), Herbalife Nutrition (HLF), Prestige Consumer Healthcare (PBH), Nu Skin Enterprises (NUS), USANA Health Sciences (USNA), Inter Parfums (IPAR), Medifast (MED), Revlon (REV) and Nature's Sunshine Products (NATR). View all competitors.

What other stocks do shareholders of Veru own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Veru investors own include Corbus Pharmaceuticals (CRBP), Opko Health (OPK), Sorrento Therapeutics (SRNE), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Viking Therapeutics (VKTX), Alibaba Group (BABA), Genocea Biosciences (GNCA), Novavax (NVAX) and Zynerba Pharmaceuticals (ZYNE).

Who are Veru's key executives?

Veru's management team includes the following people:

Dr. Mitchell S. Steiner M.D., F.A.C.S, Chairman, Pres & CEO (Age 58)
Dr. Harry Fisch, Vice Chairman & Chief Corp. Officer (Age 60)
Mr. O. B. Parrish, Co-Founder & Director (Age 86)
Ms. Michele Greco, CFO, Exec. VP of Fin. & Chief Admin. Officer (Age 60)
Dr. K. Gary Barnette Ph.D., Chief Scientific Officer (Age 51)

What is Veru's stock symbol?

Veru trades on the NASDAQ under the ticker symbol "VERU."

Who are Veru's major shareholders?

Veru's stock is owned by many different retail and institutional investors. Top institutional shareholders include Geode Capital Management LLC (0.59%), Wedge Capital Management L L P NC (0.51%), Morgan Stanley (0.50%), EAM Investors LLC (0.48%), BlackRock Inc. (0.35%) and Wells Fargo & Company MN (0.20%). Company insiders that own Veru stock include Harry Fisch, Jesus Socorro, K Gary Barnette, Michele Greco and Mitchell Shuster Steiner. View institutional ownership trends for Veru.

Which major investors are selling Veru stock?

VERU stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., and State Street Corp. View insider buying and selling activity for Veru.

Which major investors are buying Veru stock?

VERU stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley, Two Sigma Investments LP, Caxton Associates LP, Acadian Asset Management LLC, Two Sigma Advisers LP, Citigroup Inc., UBS Group AG, and Engineers Gate Manager LP. Company insiders that have bought Veru stock in the last two years include Harry Fisch, Jesus Socorro, K Gary Barnette, and Michele Greco. View insider buying and selling activity for Veru.

How do I buy shares of Veru?

Shares of VERU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Veru's stock price today?

One share of VERU stock can currently be purchased for approximately $3.64.

How big of a company is Veru?

Veru has a market capitalization of $240.60 million and generates $31.80 million in revenue each year. The company earns $-12,020,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. Veru employs 171 workers across the globe.

What is Veru's official website?

The official website for Veru is www.veruhealthcare.com.

How can I contact Veru?

Veru's mailing address is 48 NW 25th Street Suite 102, Miami FL, 33127. The company can be reached via phone at 305-509-6897 or via email at [email protected]

This page was last updated on 5/25/2020 by MarketBeat.com Staff